DealBio
All collections

Investor Intelligence

11 RNA Therapeutics Investors in Europe

Investors financing European RNA therapeutics across regulatory RNA, RNA editing, non-coding RNA and oligonucleotide medicines.

Published
  • RNA Therapeutics
  • Biotechnology
  • RNA Editing
  • Europe
  • Seed
  • Series A

now span several distinct approaches, from medicines that regulate gene expression to targeted and oligonucleotides designed to alter disease-related cellular states. European companies are attracting both specialist life-sciences funds and broader biotechnology investors as these platforms move toward clinical development.

DealBio selected 11 investors with evidenced relevance to RNA therapeutics in Europe, using current investor research, financing precedents and public verification where needed.

4See Ventures

Early-stage life-sciences investor backing biotechnology companies.

Stage
Series A
Sector / Focus
RNA therapeutics · Precision medicine · Cardiovascular health
Investment markets
Switzerland · Europe
Investor type
VC

Relevant investment

4See Ventures backed HAYA Therapeutics and participated in its $65 million Series A in 2025. HAYA develops programmable medicines targeting regulatory RNAs to reprogramme disease-driving cell states, giving 4See repeated exposure to -guided therapeutics.

Alexandria Venture Investments

Strategic life-sciences venture investor associated with Alexandria Real Estate Equities.

Stage
Series A · Growth
Sector / Focus
Biotechnology · RNA therapeutics
Investment markets
Europe · United States
Investor type
Strategic VC

Relevant investment

Alexandria Venture Investments participated in HAYA Therapeutics’ $65 million Series A. HAYA is advancing programmable therapeutics that target , with applications across cardiovascular, metabolic and fibrotic disease.

ATHOS

Life-sciences investment organisation backing biotechnology companies.

Stage
Series A
Sector / Focus
Biotechnology · RNA therapeutics
Investment markets
Europe
Investor type
Investment firm

Relevant investment

ATHOS participated in HAYA Therapeutics’ $65 million Series A in 2025. HAYA’s platform targets regulatory RNAs from the non-coding genome to alter disease-driving cell states.

Bernina BioInvest

Swiss biotechnology investment firm.

Stage
Series A
Sector / Focus
RNA therapeutics · Precision medicine
Investment markets
Switzerland · Europe
Investor type
VC

Relevant investment

Bernina BioInvest participated in HAYA Therapeutics’ $65 million Series A and had backed the company in earlier rounds. The investment provides repeated exposure to regulatory-RNA drug development.

Earlybird Venture Capital

European venture firm with a dedicated health investment practice.

Stage
Series A
Sector / Focus
Health · Biotechnology · RNA therapeutics
Investment markets
Europe
Investor type
VC

Relevant investment

Earlybird co-led HAYA Therapeutics’ $65 million Series A in 2025. The financing supports clinical development of HAYA’s programmable therapeutics targeting disease-driving regulatory RNA.

Longview Ventures

Healthcare and life-sciences investment firm.

Stage
Series A
Sector / Focus
Biotechnology · RNA therapeutics
Investment markets
Europe · United States
Investor type
VC

Relevant investment

Longview Ventures participated in HAYA Therapeutics’ $65 million Series A in 2025. The round advances HAYA’s regulatory-RNA platform and lead programme toward clinical development.

+ND Capital

Life-sciences venture firm investing in therapeutics and biotechnology.

Stage
Series A
Sector / Focus
Biotechnology · RNA therapeutics
Investment markets
Europe · United States
Investor type
VC

Relevant investment

+ND Capital participated in HAYA Therapeutics’ $65 million Series A. HAYA uses regulatory RNA and functional genomics to identify and drug disease-driving cell states.

Forbion

European life-sciences venture firm investing across therapeutics from company formation through later clinical development.

Stage
Seed · Series A · Growth
Sector / Focus
Biotechnology · RNA therapeutics
Investment markets
Europe · United States
Investor type
VC

Relevant investment

Forbion invested in AIRNA, which is developing RNA-editing therapeutics that recruit naturally occurring enzymes to change specific RNA letters. The investment gives Forbion direct exposure to programmable RNA editing.

BioMedPartners

European healthcare venture investor focused on biotechnology and medical technology.

Stage
Seed · Series A
Sector / Focus
Biotechnology · RNA therapeutics
Investment markets
Switzerland · Europe
Investor type
VC

Relevant investment

BioMedPartners backed Cardior Pharmaceuticals, a German company developing therapeutics for cardiovascular disease. Cardior was later acquired by Novo Nordisk, providing BioMedPartners with a direct European RNA-therapeutics precedent.

APEX Ventures

European early-stage investor backing deep-tech and science-driven companies.

Stage
Seed
Sector / Focus
RNA therapeutics · Longevity · Drug discovery
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

APEX Ventures backed SENISCA, which develops therapeutics designed to reverse cellular senescence by restoring age-disrupted RNA-splicing regulation. The investment provides a differentiated RNA-therapeutics precedent beyond HAYA’s financing syndicate.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.